Pantoprazol G.L (Pantoprazole Sodium Sesquihydrate)

Pantoprazol G.L is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates mucosal healing and reduces further erosion.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and prevents recurrence.

• Pantoprazole binds selectively to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, inhibiting the final step of acid production. This reversible, dose‑dependent inhibition lowers gastric acidity, allowing damaged mucosa to heal and reducing acid‑related symptoms.

Pantoprazol G.L may cause a range of adverse reactions. The profile includes both frequent, mild events and rare, potentially serious conditions.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea: occasional mild upset.
• Abdominal pain: cramp‑like discomfort.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis requiring medical attention.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.
• Severe hypersensitivity: rash, angio‑edema or anaphylaxis.
• Osteoporosis‑related fractures: increased risk with long‑term use.
• Vitamin B12 deficiency: may develop after prolonged therapy.

When prescribing Pantoprazol G.L, consider the following safety measures:

• Assess renal function: dose adjustment may be required in severe impairment.
• Evaluate hepatic status: use with caution in moderate to severe liver disease.
• Review long‑term use: monitor for bone density loss and vitamin B12 levels.
• Pregnancy and lactation: prescribe only if the potential benefit outweighs risk.
• Drug‑interaction review: check concomitant medications for known interactions.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Pantoprazol G.L can affect the pharmacokinetics of several co‑administered drugs. Interaction monitoring is advised as follows:

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption and efficacy.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (clopidogrel): possible reduction in antiplatelet effect.
• Warfarin: potential alteration of INR values.
• Methotrexate: increased systemic exposure, especially at high doses.
• Digoxin: modest increase in serum levels.
• Oral contraceptives: possible decrease in hormonal efficacy.